Product Description
Basic Characteristics
Product Name | TAK-438 |
CAS Number | 1260141-27-2 |
Molecular Formula | C21H20FN3O6S |
Formula Weight | 461.46 |
Synonyms | Vonoprazan Fumarate; TAK-438; 1260141-27-2; Vonoprazan fumurate; TAK438. |
Appearance | White to off-white powder |
Storage and Handling | Dry, dark and at 0 – 4 C for short term (days to weeks) or -20 C for long term (months to years). |
TAK-438 Description
TAK438, also known as Vonoprazan Fumarate, is a new medicine for treating acid-related diseases with a novel mechanism of action called potassium-competitive acid blockers (P-CABs) which competitively inhibits the binding of potassium ions to H+,K+-ATPase (also known as the proton pump) in the final step of gastric acid secretion in gastric parietal cells, controls gastric acid secretion. It provides a strong and sustained acid secretion inhibitory effect.
In cultured gastric glands, TAK-438 treatment resulted in a longer and stronger acid formation inhibition. The inhibition effect of TAK-438 on acid secretion seemed to be associated with gastric parietal cell physiology.
TAK-438 Mechanism of Action
TAK-438 (Vonoprazan fumarate) is a pyrole derivative and potassium-competitive acid blocker (P-CAB) that competitively blocks the potassium-binding site of gastric H(+),K(+)-ATPase, a key enzyme in the process of gastric acid secretion. The compound can accumulate in acid environments and should provide a longer duration of inhibition due to an alkaline pKa of 9.06.
In cultured gastric glands, TAK-438 treatment resulted in a longer and stronger acid formation inhibition. The inhibition effect of TAK-438 on acid secretion seemed to be associated with gastric parietal cell physiology.
TAK-438 Application
TAK-438 (Vonoprazan fumarate or Vonoprazan) is a new medicine for treating acid-related diseases with a novel mechanism of action called potassium-competitive acid blockers (P-CABs) which competitively inhibits the binding of potassium ions to H+,K+-ATPase (also known as the proton pump) in the final step of gastric acid secretion in gastric parietal cells. The drug is approved in Japan for the treatment of acid-related diseases, including gastric ulcer, duodenal ulcer, reflux esophagitis and Adjunct to Helicobacter pylori eradication in the case of Helicobacter pylori gastritis.
TAK-438 Side Effects & Warning
The common side effects included:
▪ diarrhoea,
▪ nausea and vomiting,
▪ constipation,
▪ abdominal pain,
▪ skin rash,
▪ heartburn.
These are not all the possible side effects of TAK438. For more information, ask your doctor or pharmacist. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.